Aim: To compare the bioavailability of two cetirizine tablet (10 mg) formulations (Zyrtec® from UCB Pharma, Spain as a reference formulation and Ryvel® from Novell Pharmaceutical Laboratories, Indonesia as a test formulation. Material and methods: The study was conducted according an open, randomized, two-period crossover design with a 1-week washout period. Eighteen volunteers participated and all completed the study successfully. Blood samples were obtained prior to dosing and at 0.25, 0.5, 1, 2, 3, 5, 8, 12, 24 and 30 hours after drug administration. Plasma concentrations of cetirizine were monitored using high performance liquid chromatography over a period of 30 hours after administration. The pharmacokinetics parameter AUC 0-30h , AUC 0-∞ and C max were tested for bioequivalence after log-transformation of data and ratios of T max were evaluated non-parametrically. Result: The point estimates and 90% confidence intervals for AUC 0-30h, AUC 0-∞ and C max were 108. 23% (101.90-114 
Introduction
Cetirizine {2-[4-[(4-chlorophenylmethyl]-1-piperazinyl]ethoxy} acetic acid dihydrochloride is described as a non-sedating antihistamine which is long acting and has some mast cell stabilizing activity.
Cetirizine is rapidly absorbed from the gastrointestinal tract after oral administration, peak plasma concentration being attained within about one hour. Food delays the time to peak plasma concentration but dose not decreased the amount of drug absorbed. Cetirizine is approximately 93% bound to plasma protein and has an elimination half life of about 7-11 hours. Cetirizine is excreted primarily in the urine mainly as unchanged drug. [Moffat et al. 2004] This study was intended to evaluate the bioequivalence of 10 mg cetirizine tablet manufactured by Novell Pharmaceutical Laboratories, Indonesia with the international reference tablet manufactured by UCB Pharma, Spain.
Subjects and methods
Eighteen healthy adult male volunteers participated in this study. The ages of subjects were between 18 and 32 years (25.1 ± 3.8 years), the body weights of subjects were between 42-82 kg (57.4 ± 9.3 kg) and the heights of subjects were between 155-174.5 cm (165.7 ± 7.1 cm). Demographic data of subjects are given in Table  1 . The sample size n=18 subjects was based on the previous reports [Lefebvre et al. 1988 , Muscara et al. 1995 . Subjects were selected after passing a clinical screening procedure including a physical examination, ECG and clinical laboratory tests (blood glucose, urea, creatinine, sGPT, sGOT, alkaline phosphatase, gamma GT, total bilirubin, total protein, albumin, sodium, potassium, chloride, hemoglobin, hematocrit, WBC, RBC and urine analysis). Volunteers were excluded if they had a history of any illness of hepatic, renal and cardiovascular system, or had taken alcohol or other medications for long period of time. This study was performed according to the Declaration of Helsinki for biomedical research involving human subjects and the rules of Good Clinical Practice. The protocol of this study was reviewed by the Committee of The Medical Research Ethics of the Faculty of Medicine University of Indonesia and was approved by National Agency of Drug and Food Control, Indonesia. All participants signed a written informed consent after they had been informed of the nature and details of the study in All subjects avoided using other drugs for at least two weeks prior the study and until after its completion. They also refrained from ingesting alcohol, caffeine, chocolate, tea or cokecontaining beverages at least 24 hours before each dosing and until the collection of the last blood sample. Each volunteer received an oral dose of 10 mg of cetirizine in a standard two way crossover randomized study. The dose was taken with 240 ml of tap water. There was a 1-week washout period between the doses. Subjects were asked to fast from 10 hours before until 4 hours after drug administration. The dietary regimen similar for all subjects in both trial periods consist of five standard meals served at 4, 8, 12, 24 and 28 hours after dosing. Carbohydrate is the main composition of the meals. Water was permitted two hours after drug administration.
Serial venous blood samples (5 mL) were collected at pre dose, 0.25, 0.5, 1, 2, 3, 5, 8, 12, 24 and 30 hours after the administration in heparinized tubes. After blood separation, plasma was frozen at -20ºC till drug analysis.
HPLC assay of cetirizine in plasma
The concentrations of cetirizine in plasma were analyzed using HPLC method with ultraviolet detector [Macek et al. 1999] in the Clinisindo Laboratories (Jakarta, Indonesia) following the GLP rules. The mobile phase was acetonitrile : phosphate buffer pH 6.8 (38:62) pumped isocratically at 1 ml/min through a Lichrospher RP-18 5µm, 125 mm x 4 mm i.d column (L Merck, Darmstadt, Germany) heated to 40°C. Gradient elution was employed for removing the late-eluting peaks. The wavelength was set at 232 nm. Briefly, a 10 µL aliquot of internal standard (diazepam, 20 µg/mL in methanol) was added to a 500 µL aliquot of plasma sample. After mixing, the mixture was extracted in 4 mL dichloromethane. After centrifugation, the organic phase was removed and evaporated to dryness under vacuum at 60°C. The residue was reconstituted with 100 µL of mobile phase. A 20 µL aliquot will be injected into the HPLC column. The analytical method was conveniently validated [FDA 2001 , Shah et al 2000 . The assay was linear over the concentration range of 12-800 ng/mL. 
Pharmacokinetic and statistical analysis
The bioequivalence was tested using the primary parameters, AUC 0-30h, AUC 0-∞ and C max. The maximum plasma concentrations (C max ) and time to reach maximum plasma concentrations (t max ) were obtained directly by inspection of the individual drug plasma concentration time data, and were used as measures of rate of absorption. The area under the plasma concentration time curve up to the last time (t) showing a measurable concentration (C t ) of the analyte (AUC 0-30h ) was calculated using the trapezoidal rule. The elimination rate constant (K el ) was calculated by the technique of leastsquares regression from the data of the last 3-5 points of each plasma concentration time curve. The AUC 0-∞ value was computed using the equation AUC 0-∞ = AUC 0-30h + *C t /K el Where *C t is the estimated last plasma concentration. The apparent elimination half-life (t ½ ) of cetirizine in plasma was determined by using the following equation t 1/2 = (ln2)/K el For the parameters of AUC 0-30h , AUC 0-∞ , and C max , a multiplicative model was assumed, and analysis of variance (ANOVA) was applied using the respective ln-transformed data. For estimation of bioequivalence the 90% confidence of intervals of the geometric mean ratio test/reference for AUC 0-30h , AUC 0-∞ ,and C max were calculated assuming a multiplicative model. The accepted bioequivalence range for these parameters was 80% and 125%. All statistical analysis was performed using EquivTest 2.0 statistical program. 
Result and discussion
All 18 volunteers successfully completed the trial according to the protocol. Both cetirizine formulations were well-tolerated at the administered dose and no serious adverse clinical events were observed. In this study, plots individual plasma profiles for both formulations are depicted in Figure 1 and the mean cetirizine concentration versus time profiles for both formulations are shown in Figure 2 . The ratio of AUC 0-30h / AUC 0-∞ for all individuals and for both products was 0.90 or above, indicate an adequate sampling time, since the extrapolated portion of the total AUC is less than 20%.
The pharmacokinetic parameters used to assess the bioequivalence of the test formulation versus the reference were AUC 0-30h , AUC 0-∞ for the extent of the absorption and C max and t max for the rate of absorption. Descriptive statistics of the pharmacokinetic parameter for cetirizine test and reference preparations are summarized in Table 2 with shows the geometric mean values and the range for the AUC 0-30h , AUC 0-∞ , C max , and t ½ values obtained for each formulation. The pharmacokinetic characteristic t max is presented as mean (± SD). The results of the bioequivalence analysis are given in The intra-individual variations in the AUC 0-30h , AUC 0-∞ , C max and t 1/2 estimated from the coefficients of variation as determined by ANOVA were 10.34%, 10.10%, 17.23% and 8.37%, respectively.
In conclusion, the two cetirizine formulations are equivalent with respect to the rate and extent of absorption and it can be assumed to be therapeutically equivalent and exchangeable in clinical practice. This study was supported by PT Novell Pharmaceutical Laboratories, Jakarta, Indonesia
